First Horizon Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $54.4K | Buy |
433
+48
| +12% | +$6.03K | ﹤0.01% | 956 |
|
|
2025
Q1 | $42.6K | Sell |
385
-480
| -55% | -$53.1K | ﹤0.01% | 1006 |
|
|
2024
Q4 | $118K | Sell |
865
-142
| -14% | -$19.4K | ﹤0.01% | 648 |
|
|
2024
Q3 | $116K | Buy |
1,007
+176
| +21% | +$20.3K | ﹤0.01% | 676 |
|
|
2024
Q2 | $114K | Buy |
831
+49
| +6% | +$6.75K | ﹤0.01% | 653 |
|
|
2024
Q1 | $108K | Hold |
782
| – | – | ﹤0.01% | 670 |
|
|
2023
Q4 | $103K | Buy |
782
+74
| +10% | +$9.75K | ﹤0.01% | 658 |
|
|
2023
Q3 | $79.7K | Hold |
708
| – | – | ﹤0.01% | 693 |
|
|
2023
Q2 | $66.8K | Sell |
708
-11
| -2% | -$1.04K | ﹤0.01% | 771 |
|
|
2023
Q1 | $72.8K | Hold |
719
| – | – | ﹤0.01% | 738 |
|
|
2022
Q4 | $85.9K | Buy |
719
+65
| +10% | +$7.76K | ﹤0.01% | 667 |
|
|
2022
Q3 | $69K | Sell |
654
-45
| -6% | -$4.75K | ﹤0.01% | 730 |
|
|
2022
Q2 | $67K | Buy |
699
+191
| +38% | +$18.3K | ﹤0.01% | 829 |
|
|
2022
Q1 | $48K | Sell |
508
-421
| -45% | -$39.8K | ﹤0.01% | 657 |
|
|
2021
Q4 | $78K | Sell |
929
-103
| -10% | -$8.65K | ﹤0.01% | 771 |
|
|
2021
Q3 | $98K | Buy |
1,032
+304
| +42% | +$28.9K | ﹤0.01% | 673 |
|
|
2021
Q2 | $70K | Buy |
728
+48
| +7% | +$4.62K | ﹤0.01% | 658 |
|
|
2021
Q1 | $65K | Buy |
680
+12
| +2% | +$1.15K | ﹤0.01% | 642 |
|
|
2020
Q4 | $63K | Buy |
668
+245
| +58% | +$23.1K | ﹤0.01% | 530 |
|
|
2020
Q3 | $40K | Buy |
423
+248
| +142% | +$23.5K | ﹤0.01% | 607 |
|
|
2020
Q2 | $21K | Hold |
175
| – | – | ﹤0.01% | 788 |
|
|
2020
Q1 | $15K | Buy |
175
+38
| +28% | +$3.26K | ﹤0.01% | 837 |
|
|
2019
Q4 | $15K | Hold |
137
| – | – | ﹤0.01% | 967 |
|
|
2019
Q3 | $12K | Sell |
137
-7
| -5% | -$613 | ﹤0.01% | 1025 |
|
|
2019
Q2 | $12K | Hold |
144
| – | – | ﹤0.01% | 1036 |
|
|
2019
Q1 | $13K | Buy |
+144
| New | +$13K | ﹤0.01% | 976 |
|